AstraZeneca lung cancer drug Tagrisso approved by EU regulators - Sharecast.com

AstraZeneca's Tagrisso approved by EU regulators for EGFR-mutated NSCLC, reducing disease progression risk by 84% in LAURA trial. This marks the fifth major approval globally, with applications under review in China, Japan, and others.


Related News

AstraZeneca lung cancer drug Tagrisso approved by EU regulators - Sharecast.com

AstraZeneca's Tagrisso approved by EU regulators for EGFR-mutated NSCLC, reducing disease progression risk by 84% in LAURA trial. This marks the fifth major approval globally, with applications under review in China, Japan, and others.

© Copyright 2024. All Rights Reserved by MedPath